The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Novo will drop the lawsuit it filed against Hims & Hers in February and start selling its popular GLP-1 medicine brands Ozempic and Wegovy on the telehealth platform. Hims & Hers, on the other hand, ...

On Monday morning, Novo Nordisk, the makers of the GLP-1 drug semaglutide (Ozempic and Wegovy), and Hims & Hers Health Inc. jointly announced a ceasefire to their growing hostilities via a new ...

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

Hims & Hers and Novo Nordisk have officially laid down their swords. | The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its ...

Hims & Hers stock traded more than 40% higher after the deal was announced.

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and Wegovy copycat drugs.

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the ...